DOP071 Tight control with adalimumab-based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM
暂无分享,去创建一个
G. D'Haens | F. Baert | M. Skup | W. Reinisch | R. Panaccione | A. Armuzzi | G. Novacek | J. Colombel | R. Thakkar | J. Petersson | P. Bossuyt | N. Chen | A. Danalıoğlu | A. Robinson | W. Lee | T. Van̆ásek | E. Neimark | W. Lee